IRulya Therapeutics (IRLA) News
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.88-0.06 (-0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRLA news summary
We found 2 recent headlines mentioning IRulya Therapeutics (IRLA): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire. For price context, IRLA is down 0.15% at $39.88. The most recent story, "IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest IRulya Therapeutics headlines
- IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsName changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026GlobeNewswire
- IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying…GlobeNewswire